Evidence map›Paper›PMID 37232808›Full record

ReviewCurrent oncology (Toronto, Ont.)2023

Intravesical Contrast-Enhanced MRI: A Potential Tool for Bladder Cancer Surveillance and Staging.

Pradeep Tyagi, Chan-Hong Moon, Marc Connell, Anirban Ganguly, Kang Jun Cho, Tatum Tarin, Rajiv Dhir, Biatta Sholosh, Jodi Maranchie

Open access · goldAbstract readReview
In one paragraph

Review in Current oncology (Toronto, Ont.), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
3.5field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 11 citations in OpenAlex.

  1. The Stalk Sign in Bladder Cancer: CEUS Versus MRI.Diagnostics (Basel, Switzerland) · 2026
    Article
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Pradeep TyagiDepartment of Urology, School of Medicine, University of Pittsburgh, Pittsburgh, PA 15213, USA.ORCID 0000-0001-6586-4545
Chan-Hong MoonDepartment of Urology, School of Medicine, University of Pittsburgh, Pittsburgh, PA 15213, USA.
Marc ConnellDepartment of Urology, School of Medicine, University of Pittsburgh, Pittsburgh, PA 15213, USA.
Anirban GangulyDepartment of Urology, School of Medicine, University of Pittsburgh, Pittsburgh, PA 15213, USA.
Kang Jun ChoDepartment of Urology, School of Medicine, University of Pittsburgh, Pittsburgh, PA 15213, USA.ORCID 0000-0002-5305-901X
Tatum TarinDepartment of Urology, School of Medicine, University of Pittsburgh, Pittsburgh, PA 15213, USA.
Rajiv DhirDepartment of Urology, School of Medicine, University of Pittsburgh, Pittsburgh, PA 15213, USA.
Biatta SholoshDepartment of Urology, School of Medicine, University of Pittsburgh, Pittsburgh, PA 15213, USA.
Jodi MaranchieDepartment of Urology, School of Medicine, University of Pittsburgh, Pittsburgh, PA 15213, USA.
University of Pittsburgh · US

Funding

Advancing Bladder Cancer Care by Imaging and Intravesical Immune Checkpoint BlockadeR21CA263243 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI TYAGI, PRADEEP · 2022 to 2023
$391k
Virtual Histology of the Bladder Wall for Bladder Cancer StagingR21CA252590 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI MARANCHIE, JODI KATHLEEN, TYAGI, PRADEEP · 2020 to 2020
$326k
NCI NIH HHS R21 CA252590NCI NIH HHS R21 CA263243
6 · The paper itself

Abstract

This review article gives an overview of the current state of the art of bladder cancer imaging and then discusses in depth the scientific and technical merit of a novel imaging approach, tracing its evolution from murine cancer models to cancer patients. While the poor resolution of soft tissue obtained by widely available imaging options such as abdominal sonography and radiation-based CT leaves them only suitable for measuring the gross tumor volume and bladder wall thickening, dynamic contrast-enhanced magnetic resolution imaging (DCE MRI) is demonstrably superior in resolving muscle invasion. However, major barriers still exist in its adoption. Instead of injection for DCE-MRI, intravesical contrast-enhanced MRI (ICE-MRI) instills Gadolinium chelate (Gadobutrol) together with trace amounts of superparamagnetic agents for measurement of tumor volume, depth, and aggressiveness. ICE-MRI leverages leaky tight junctions to accelerate passive paracellular diffusion of Gadobutrol (604.71 Daltons) by treading the paracellular ingress pathway of fluorescein sodium and of mitomycin (<400 Daltons) into bladder tumor. The soaring cost of diagnosis and care of bladder cancer could be mitigated by reducing the use of expensive operating room resources with a potential non-surgical imaging option for cancer surveillance, thereby reducing over-diagnosis and over-treatment and increasing organ preservation.

Indexed as

Organometallic CompoundsUrinary Bladder NeoplasmsAnimalsHumansMagnetic Resonance ImagingMiceNeoplasm StaginggadobutrolOrganometallic Compoundsbladder cancergadoliniumintravesicalMRIstaging

Identifiers

PMID37232808
PMCPMC10217503
OpenAlexW4367852910

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.